Phathom Pharmaceuticals

Novel treatments for gastrointestinal diseases and disorders

Also NDA errosive GERD, heartburn, Clin3 heartburn in non-erosive GERD, different dosing Clin2 heartburn in non-erosive GERD, Clin2 eosinophilic esophagitis

Phathom Pharmaceuticals is dedicated to improving treatments for gastrointestinal (GI) diseases. They focus on developing innovative therapies for acid-related disorders like ulcers and heartburn. One key area of their research is the development of new proton pump inhibitors – a class of drugs that reduce stomach acid production. While there are existing PPIs on the market, Phathom is investigating more effective and potentially longer-lasting options. This could lead to improved patient outcomes and potentially reduce the need for frequent medication use.